Current Liabilities
Contract Liabilities
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
Metric ID:
contract_liabilitiesProduct Breakdown
| Segment | Q4 '21 | Q4 '22 | Q4 '23 | Q4 '25 |
|---|---|---|---|---|
| Paxlovid and Comirnaty | — | — | — | $1.5B |
| Comirnaty | — | $2.5B | — | — |
| Paxlovid | $0 | — | $1.5B | — |
| Total | — | — | — | — |
Paxlovid was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
